Applied DNA Sciences has restructured to focus on synthetic DNA manufacturing by closing its clinical lab and cutting 27% of staff, aiming to reduce costs and scale nucleic acid therapy production. Meanwhile, Tempus AI announced plans to raise $400 million through convertible senior notes to repay debt amidst ongoing shareholder litigation. Apple Tree Partners warns of imminent portfolio biotech collapses amid investor disputes. These moves highlight challenges biotech firms face in capital markets and strategic shifts to prioritize high-growth assets and financial stability.